Clinical Trial Update: Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of Epirubicin (Pharmorubicin), Carboplatin (Paraplatin) and Capecitabine (Xeloda) for unresectable locally advanced or metastatic gastric or g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Paraplatin (Carboplatin)
• Pharmorubicin (pharmorubicin)
• Xeloda (capecitabine)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Gastric Cancer, Esophageal Cancer | Phase 1, Phase 2 | Status: TERMINATED